Comment on “Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison” [Letter]
Bhaskar Rege,1 Jonathan M Meyer2 1Pharmaceutical & Early Stage Clinical Development, Alkermes, Inc., Waltham, MA, USA; 2Department of Psychiatry, University of California, San Diego, CA, USACorrespondence: Bhaskar Rege, Alkermes, Inc., 852 Winter Street, Waltham, MA, 02451, USA, Email Bhaska...
Main Authors: | Rege B, Meyer JM |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-07-01
|
Series: | Neuropsychiatric Disease and Treatment |
Subjects: | |
Online Access: | https://www.dovepress.com/comment-on-ldquoaripiprazole-plasma-concentrations-delivered-from-two--peer-reviewed-fulltext-article-NDT |
Similar Items
-
Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison
by: Harlin M, et al.
Published: (2023-06-01) -
Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
by: Chih-Sung Liang, et al.
Published: (2021-11-01) -
Assessment of hospitalizations in schizophrenia patients treated with paliperidone 1-monthly (PP1M), paliperidone 3-monthly (PP3M), aripiprazole once-monthly (AOM) and other oral antipsychotics (OAP) in clinical practice
by: L. Gutiérrez Rojas, et al.
Published: (2021-04-01) -
Long-acting injectable antipsychotics during pregnancy: An update
by: A. Paraschakis, et al.
Published: (2021-04-01) -
Clinical use of long-acting antipsychotics for the treatment of bipolar disorder type I patients
by: Derya Gül Bilen, et al.
Published: (2022-06-01)